HIF inhibitors in clinical studies have shown modest results and high toxicity (83), therefore, HIF inhibition should be approached in a more holistic way, modulating for example the external factors that lead to HIF-1α activation in the tumor context. This evidence concerns the gene HIF1A and neoplasm.